Abstract
The present study investigated the effects of myo-inositol on muscle glucose uptake and intestinal glucose absorption ex vivo as well as in normal and type 2 diabetes model of rats. In ex vivo study, both intestinal glucose absorption and muscle glucose uptake were studied in isolated rat jejunum and psoas muscle respectively in the presence of increasing concentrations (2.5 % to 20 %) of myo-inositol. In the in vivo study, the effect of a single bolus dose (1 g/kg bw) of oral myo-inositol on intestinal glucose absorption, blood glucose, gastric emptying and digesta transit was investigated in normal and type 2 diabetic rats after 1 h of co-administration with 2 g/kg bw glucose, when phenol red was used as a recovery marker. Myo-inositol inhibited intestinal glucose absorption (IC50 = 28.23 ± 6.01 %) and increased muscle glucose uptake, with (GU50 = 2.68 ± 0.75 %) or without (GU50 = 8.61 ± 0.55 %) insulin. Additionally, oral myo-inositol not only inhibited duodenal glucose absorption and reduced blood glucose increase, but also delayed gastric emptying and accelerated digesta transit in both normal and diabetic animals. Results of this study suggest that dietary myo-inositol inhibits intestinal glucose absorption both in ex vivo and in normal or diabetic rats and also promotes muscle glucose uptake in ex vivo condition. Hence, myo-inositol may be further investigated as a possible anti-hyperglycaemic dietary supplement for diabetic foods and food products.
This is a preview of subscription content, access via your institution.





Abbreviations
- DBC:
-
Diabetic control
- DMI:
-
Diabetic myo-inositol
- GAI:
-
Glucose absorption index
- GIT:
-
Gastrointestinal tract
- NC:
-
Normal control
- NMI:
-
Normal myo-inositol
- PCOS:
-
Polycystic ovary syndrome
- PR:
-
Phenol red
- T2D:
-
Type 2 diabetes
References
Algandaby MM, Alghamdi HA, Ashour OM, et al. (2010) Mechanisms of the antihyperglycemic activity of Retama raetam in streptozotocin-induced diabetic rats. Food Chem Toxicol 48:2448–2453
Aronoff SL, Berkowitz K, Shreiner B, Want L (2004) Glucose metabolism and regulation: beyond insulin and glucagon diabetes. Spectr 17:183–190
Bessesen DH (2001) The role of carbohydrates in insulin resistance. J Nutr 131:2782–2786
Brown RJ, De Banate MA, Rother KI (2010) Artificial sweeteners: a systematic review of metabolic effects in youth. Int J Pediatr Obes 5:305–312
Chung SK, Kwon YU (1999) Practical synthesis of all inositol stereoisomers from myo-inositol. Bioorg Med Chem Lett 9:2135–2140
Clements RS Jr, Darnell B (1980) Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr 33:1954–1967
Dang NT, Mukai R, Yoshida K, Ashida H (2010) D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci Biotechnol Biochem 74:1062–1067
Dedoussis GVS, Kaliora AC, Panagiotakos DB (2007) Genes, Diet and Type 2 Diabetes Mellitus: A Review. Rev Diab Stud 4:13–24
Facchinetti F, Bizzarri M, Benvenga S, et al. (2015) Results from the international consensus conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol 195:72–76
French AB, Brown IF, Good CJ, McLeod GM (1968) Comparison of phenol red and polyethyleneglycol as non-absorbable markers for the study of intestinal absorption in humans. Am J Dig Dis 13:558–564
Giordano D, Corrado F, Santamaria A, et al. (2011) Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause 18:102–104
Hassan Z, Yam MF, Ahmad M, Yusof AP (2010) Anti-diabetic properties and mechanism of action of Gynuraprocumbens water extract in streptozotocin – induced diabetic rats. Molecules 15:9008–9025
Heimark D, McAllister J, Larner J (2014) Decreased myo-inositol to chiro-inositol (M/ C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 61:111–117
Horowitz M, Wishart JM, Jones KL, Hebbard GS (1996) Gastric emptying in diabetes: an overview. Diabet Med 13:S16–S22
Hu FB (2003) Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipids 38:103–108
International Diabetes Federation (2015) IDF Diabetes Atlas. 7th edition
Islam MS, Sakaguchi E (2006) Sorbitol-based osmotic diarrhea: possible causes and mechanism of prevention investigated in rats. World J Gastroenterol 12:7635–7641
Kunjara S, Wang DY, Greenbaum AL, McLean P, Kurtz A, Rademacher TW (1999) Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changes. Mol Genet Metab 68:488–502
Livesey G (2003) Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties. Nutr Res Rev 16:163–191
Loghmani E (2005) Diabetes mellitus: type 1 and type 2. In: Stang J (ed) Guide lines for adolescent nutrition service. University of Minnesota, Minneapolis, pp. 167–182
Maeba R, Hara H, Ishikawa H, et al. (2008) Myoinositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J Nutr Sci Vitaminol (Tokyo) 54:196–202
McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE (2000) Inositol stereoisomers stabilize on oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Abeta-induced toxicity. J Biol Chem 275:18495–18502
McLean P, Kunjara S, Greenbaum AL, et al. (2008) Reciprocal control of pyruvate dehydrogenase kinase and phosphatase by inositol phosphoglycans. Dynamic state set by "push-pull" system. J Biol Chem 283:33428–33436
Minozzi M, Nordio M, Pajalich R (2013) The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 17:537–540
Montonen J, Järvinen R, Knekt P, Heliövaara M, Reunanen A (2007) Consumption of sweetened beverages and intakes of fructose and glucose predict type 2 diabetes occurrence. J Nutr 137:1447–1454
Nordio M, Proietti E (2012) The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 16:575–581
Onomi S, Katayama T (1997) Effects of dietary myo-inositol and phytic acid on hepatic lipids accumulation in rats fed on sucrose or orotic acid. J Jpn Soc Nutr Food Sci 50:267–272
Partley RE (2013) The early treatment of type 2 diabetes. Am J Med 126:S2–S9
Phillips WT, Schwartz JG, McMahan CA (1991) Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. N Engl J Med 324:130–131
Ranganath L, Norris F, Morgan L, Wright J, Marks V (1998) Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med 15:120–124
Rider AK, Schedl HP, Nokes G, Shining S (1967) Small intestinal glucose transport. Proximal-distal kinetic gradients. J Gen Physiol 50:1173–1182
Riesenfeld G, Sklan D, Bar A, Eisner U, Hurwitz S (1980) Glucose absorption and starch digestion in the intestine of the chicken. J Nutr 110:117–121
Salminen E, Salminen S, Porkka L, Koivistoinen P (1984) The effects of xylitol on gastric emptying and secretion of gastric inhibitory polypeptide in the rat. J Nutr 114:2201–2203
Saltiel AR (1990) Second messengers of insulin action. Diabetes Care 13:244–256
Shafer RB, Levine AS, Marlette JM, Morley JE (1987) Effects of xylitol on gastric emptying and food intake. Am J Clin Nutr 45:744–747
Stanhope KL, Bremer AA, Medici V, et al. (2011) Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab 96:E1596–E1605
Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP (2014) Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 21:854–858
Uusitupa M (2002) Lifestyles matter in the prevention of type 2 diabetes. Diabetes Care 25:1650–1651
Wilson RD, Islam MS (2012) Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes. Pharmacol Rep 64:129–139
Yap A, Nishiumi S, Yoshida K, Ashida H (2007) Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives. Cytotechnol 55:103–108
Acknowledgments
This study was supported by the competitive research grant from the Research Office, University of KwaZulu-Natal (UKZN), Durban; an incentive grant for rated researchers and a grant support for women and young researchers from the National Research Foundation (NRF), Pretoria, South Africa. Special thanks to Dr. M. Singh for giving us access to her lab and Dr. Linda Bester, David Mompe and Deliwe Mdakane for their assistance during this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors declare that there is no conflict of interest within this article.
Rights and permissions
About this article
Cite this article
Chukwuma, C.I., Ibrahim, M.A. & Islam, M.S. Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: a dual approach study. J Physiol Biochem 72, 791–801 (2016). https://doi.org/10.1007/s13105-016-0517-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13105-016-0517-1
Keywords
- Myo-inositol
- Type 2 diabetes
- Intestinal glucose absorption
- Muscle glucose uptake
- Rats